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Retinal vein occlusion (RVO) affects 16 million people 
worldwide, usually the middle-aged or older. It is caused by 
thrombosis, the clogging of the retinal veins, which may occur in the 
four branch veins – branch vein retinal occlusion (BVRO), or in the 
central vein, which is formed by the combination of the four branch 
veins – central vein retinal occlusion (CVRO). Left untreated (or if 
treatment fails), persistant RVO can lead to macular edema (ME), the 
swelling of thickening of the macula caused by leaking blood 
vessels. 
The standart care was grid laser photocoagulation for ME and 
non-ischemic BRVO and observation of macular edema in the case 
of CRVO. Today, care differs: implantable and injectable drug-based 
options are available, notably a dexamethasone intravitreal implant 
(Allergan’s Ozurdex) and inhibitors of vascular endothelial grows 
factor (VEGF), including an antibody and a fusion protein. Recently, 
pars plana vitrectomy has also been shown to be effective for 
improving macular thickness, volume, and sensitivity in patients with 
ME secondary to ischemic CRVO. 
Dexamethasone is a potent, water-soluble corticosteroid with 
many therapeutic indications, mostly anti-inflammatory. The 
intravitreal dexamethasone-containing implant comprises micronized 
dexamethasone within a biodegradable copolymer of lactic and 
glycolic acids. The implant is inserted into the eye through a small 
pars plana puncture using a customized applicator system and it 
releases dexamethasone over a period of months.  
It has been demonstrated that high concentrations of 
dexamethasone are sustained in the retina and vitreous during the 
first 2 months after the injection, and lower concentrations are 
sustained up to 6 months. Ozurdex has been proven effective, 
approved by the regulatory agencies in the United States and Europe, 
and is currently used in clinical practice for the treatment of ME 
associated with RVO and noninfectious posterior uveitis. It has also 
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been demonstrated to be effective for the treatment of diabetic ME in 
vitrectomized eyes. 
All published studies of Ozurdex focused on its short-term 
efficacy and safety, following patients for 6 or 12 months only. 
Information regarding the response to multiple treatments, the 
optimal retreatment interval, and long-term follow-up is lacking. The 
purpose of this study is to evaluate the long-term visual prognosis 
and complications of patients who received Ozurdex injections for 
the treatment of ME in RVO. 
VEGF inhibitors such as ranibizumab revealed a beneficial 
effect on visual function and reduced central macular thickness in 
eyes with BRVO and CRVO. However, with respect to the shorter 
half-life of ranibizumab, numerous injections are required to achieve 
and maintain this therapeutic effect. This is also valid for 
bevacizumab which is injected every 6 weeks for 12 months with a 
significant improvement of visual acuity (VA) and reduction of 
macular edema. 
A pre-treatment with a VEGF inhibitor may have an impact 
on the time until a recurrence of macular edema following the first 
Ozurdex implantation is seen. However, it appeared that the time to 
recurrence could not be prolonged. Recurrences occurred after a 
period of 3.2 and 3.8 months. Interestingly, the number of 
recurrences (and subsequent retreatments) in patients receiving a 
monotherapy with the dexamethasone implant was lower in BRVO 
compared with CRVO patients, which may be well explained by the 
more favorable natural course of macular edema associated with 
BRVO. 
In conclusion, combined treatment using Avastin 
(bevacizumab) and Ozurdex showed slightly better functional 
outcome for CRVO patients. Increased intraocular pressure and 
cataract progression was frequent and should be considered when an 
individual treatment is planned. 
 
 
 
